Listing 1 - 4 of 4 |
Sort by
|
Choose an application
Alzheimer’s disease, currently the most frequent cause of dementia in the elderly, is characterized by a specific and very complex pathophysiology. The latter includes defects at the level of Aβ and tau proteins, synaptic and mitochondrial dysfunctions, inflammation, and a dysregulation of cholesterol metabolism. Although the triggering factor of this disease remains unknown, many predisposing factors are known and some can be dealt with relatively early stages. With regard to therapeutics, only symptomatic treatments are currently available (Aricpet®, Reminyl®, Exelon ® and Ebixa®). In order to mitigate this shortcoming, researchers are first of all trying to understand the pathophysiology of the disease in order to establish reliable biomarkers to evaluate the molecules under clinical study. Thanks to that and to many other criteria allowing an objective evaluation of potential treatments, science is evolving and significant discoveries are made towards a forthcoming treatment modifying the pathology of Alzheimer’s disease. Among the molecules under study, the most promising are those aiming at the amyloid protein (reducing the production and aggregation of Aβ and increasing its clearance) and at the tau protein (inhibitors of phoshorylation and aggregation), as well as other potential strategies. A state-of-the art description of these potential medications is the bases of this work. La maladie d’Alzheimer, cause de démence la plus fréquente à l’heure actuelle chez la personne âgée, est caractérisée par une physiopathologie spécifique et très complexe. Cette dernière associe des défauts au niveau des protéines Aβ et tau, un dysfonctionnement synaptique et mitochondrial, de l’inflammation et une dérégulation du métabolisme du cholestérol. Bien que le facteur déclenchant de cette maladie ne soit pas encore connu, de nombreux facteurs prédisposants sont eux connus et peuvent, pour certains, être pris en charge précocement. En ce qui concerne la thérapeutique de cette pathologie, seuls des traitements symptomatiques sont disponibles actuellement (Aricpet®, Reminyl®, Exelon ® et Ebixa®). Afin de pallier ce déficit, les chercheurs tentent tout d’abord de comprendre la physiopathologie de la maladie afin d’établir des biomarqueurs fiables permettant d’évaluer les molécules en cours d’étude clinique. Grâce à cela et aux nombreux autres critères permettant une évaluation objective des traitements potentiels, la science évolue et réalise petit à petit des découvertes significatives permettant d’espérer à moyen terme traitement modifiant la pathologie d’Alzheimer. Parmi les molécules en études se trouvent notamment les substances visant la protéine amyloïde (diminution de la production et de l’agrégation d’ Aβ et augmentation de sa clairance), celles visant la protéine tau (inhibiteurs de la phosphorylation et de l’agrégation) ainsi que d’autres stratégies potentielles. Un état des lieux des thérapies en vie de développement est établi dans ce travail.
Alzheimer Disease --- Biomarkers, Pharmacological --- Amyloidogenic Proteins
Choose an application
Protein adsorption to solids, nanomaterials, and biological surfaces is of central interest in many fields, including biomedicine, bioanalytical chemistry, materials engineering, bio-nanotechnology, and basic biomolecular research. Although protein adsorption may sometimes occur with little consequence on molecular structure, interactions with surfaces frequently cause changes in local or global conformations and dynamics, perturbations to secondary structures or tertiary folds, eventually resulting in dramatically altered protein function. Importantly, surfaces may trigger protein misfolding and self-aggregation, or, conversely, promote protein structure formation. The use of nanoscale surfaces to remodel the conformational landscape and the aggregation pathways of amyloidogenic peptides and proteins has been proposed as a promising strategy against several severe human diseases. The rapid growth of applications and technological innovation which is based on or concerned with protein adsorption necessitates renewed efforts to provide molecular-level insights into adsorption-induced protein structural perturbations. In this Special Issue, we gathered the recent findings of experimental and computational investigations that contributed novel insights into protein adsorption with a focus on the structural and dynamic aspects of proteins.
Research & information: general --- Biology, life sciences --- Biochemistry --- sarcoplasmic reticulum Ca2+-ATPase --- Cu+-ATPase --- phospholipid flippase --- charge displacement --- concentration jump --- solid supported membrane --- conformational transition --- electrogenicity --- ion translocation --- phospholipid flipping --- protein-nanoparticle interactions --- protein NMR --- amyloidogenic proteins --- nitroxide paramagnetic perturbation --- spin label extrinsic probes --- Tempol --- β2-microglobulin --- protein conformation --- protein-surface association --- lipid membranes --- surface-immobilized protein --- EPR spectroscopy --- alpha-synuclein --- amyloid fibrils --- conformational flexibility --- protein adsorption --- protein aggregation --- nano-bio interface --- nanocomposite --- nanoparticles --- supramolecular assembly --- NMR spectroscopy --- gold nanoparticles --- PEGylation --- adsorption --- passivation --- sarcoplasmic reticulum Ca2+-ATPase --- Cu+-ATPase --- phospholipid flippase --- charge displacement --- concentration jump --- solid supported membrane --- conformational transition --- electrogenicity --- ion translocation --- phospholipid flipping --- protein-nanoparticle interactions --- protein NMR --- amyloidogenic proteins --- nitroxide paramagnetic perturbation --- spin label extrinsic probes --- Tempol --- β2-microglobulin --- protein conformation --- protein-surface association --- lipid membranes --- surface-immobilized protein --- EPR spectroscopy --- alpha-synuclein --- amyloid fibrils --- conformational flexibility --- protein adsorption --- protein aggregation --- nano-bio interface --- nanocomposite --- nanoparticles --- supramolecular assembly --- NMR spectroscopy --- gold nanoparticles --- PEGylation --- adsorption --- passivation
Choose an application
Protein adsorption to solids, nanomaterials, and biological surfaces is of central interest in many fields, including biomedicine, bioanalytical chemistry, materials engineering, bio-nanotechnology, and basic biomolecular research. Although protein adsorption may sometimes occur with little consequence on molecular structure, interactions with surfaces frequently cause changes in local or global conformations and dynamics, perturbations to secondary structures or tertiary folds, eventually resulting in dramatically altered protein function. Importantly, surfaces may trigger protein misfolding and self-aggregation, or, conversely, promote protein structure formation. The use of nanoscale surfaces to remodel the conformational landscape and the aggregation pathways of amyloidogenic peptides and proteins has been proposed as a promising strategy against several severe human diseases. The rapid growth of applications and technological innovation which is based on or concerned with protein adsorption necessitates renewed efforts to provide molecular-level insights into adsorption-induced protein structural perturbations. In this Special Issue, we gathered the recent findings of experimental and computational investigations that contributed novel insights into protein adsorption with a focus on the structural and dynamic aspects of proteins.
sarcoplasmic reticulum Ca2+-ATPase --- Cu+-ATPase --- phospholipid flippase --- charge displacement --- concentration jump --- solid supported membrane --- conformational transition --- electrogenicity --- ion translocation --- phospholipid flipping --- protein-nanoparticle interactions --- protein NMR --- amyloidogenic proteins --- nitroxide paramagnetic perturbation --- spin label extrinsic probes --- Tempol --- β2-microglobulin --- protein conformation --- protein-surface association --- lipid membranes --- surface-immobilized protein --- EPR spectroscopy --- alpha-synuclein --- amyloid fibrils --- conformational flexibility --- protein adsorption --- protein aggregation --- nano-bio interface --- nanocomposite --- nanoparticles --- supramolecular assembly --- NMR spectroscopy --- gold nanoparticles --- PEGylation --- adsorption --- passivation --- n/a
Choose an application
Aberrant protein folding and self-assembly underlie over 30 human diseases called amyloidoses, for which currently there is no cure. The diseases range from tissue-specific to systemic and from genetic to sporadic. Some of the most devastating amyloidoses are those that affect the central nervous system (CNS), such as Alzheimer’s disease (AD), Parkinson’s disease (PD), prionoses (e.g., mad-cow disease), and amyotrophic lateral sclerosis (Lou Gehrig’s disease). In each disease, one or more proteins self-associate into toxic oligomers that disrupt cellular function and communication, and proceed to form insoluble amyloid aggregates characterized by fibrillar morphology and cross-β structure. The first decade of the 21st century has brought with it significant progress in our understanding of amyloid diseases, including the physiological and pathological processes involving each of the offending proteins. Important developments also provide now improved diagnoses of different amyloidoses and new approaches are being developed towards disease-modifying therapies. This book covers the current state-of-the-art knowledge on amyloidoses as a general phenomenon and offers detailed reviews of individual amyloid-forming proteins and specific diseases. Features: Coverage of the pathologic and pathogenic structures of amyloidogenic proteins from the pathological lesions to the evasive oligomers that are believed to be the main culprits. Detailed discussions of diseases of epidemic proportion, such as Alzheimer’s disease, Parkinson’s disease, and type-2 diabetes. Current reviews of multiple diseases, including amyotrophic lateral sclerosis, prionoses, expanded polyglutamine diseases, dialysis-related amyloidosis, and transthyretin-related amyloidoses. Mechanism-based strategies for inhibiting protein aggregation and potential therapeutic applications in different diseases.
Amyloid. --- Degeneration (Pathology). --- Amyloidosis --- Amyloid --- Nervous System Diseases --- Noxae --- Proteins --- Toxic Actions --- Diseases --- Chemical Actions and Uses --- Amino Acids, Peptides, and Proteins --- Chemicals and Drugs --- Cytotoxins --- Neurodegenerative Diseases --- Amyloidogenic Proteins --- Human Anatomy & Physiology --- Health & Biological Sciences --- Animal Biochemistry --- Amyloidosis. --- Protein binding. --- Degeneration (Pathology) --- Degenerative diseases --- Degenerative disorders --- Binding, Protein --- Amyloid degeneration --- Medicine. --- Neurosciences. --- Pathology. --- Proteins. --- Neurobiology. --- Biomedicine. --- Biomedicine general. --- Protein Science. --- Protein Structure. --- Pathology --- Biochemistry --- Allosteric proteins --- Radioligand assay --- Lymphoproliferative disorders --- Metabolism --- Disorders --- Biochemistry. --- Disease (Pathology) --- Medical sciences --- Medicine --- Medicine, Preventive --- Neurosciences --- Neural sciences --- Neurological sciences --- Neuroscience --- Nervous system --- Biological chemistry --- Chemical composition of organisms --- Organisms --- Physiological chemistry --- Biology --- Chemistry --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Physicians --- Composition --- Proteins . --- Biomedicine, general. --- Health Workforce --- Proteids --- Biomolecules --- Polypeptides --- Proteomics
Listing 1 - 4 of 4 |
Sort by
|